In a longitudinal study of 300,000 adults with type 2 diabetes mellitus, a relative risk reduction in gout of nearly 40% has been observed among patients newly prescribed an SGLT2 inhibitor compared with those newly prescribed a glucagon-like peptide 1 (GLP1) agonist [33]. This evidence concerns the gene SLC5A2 and gout.